We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Eli Lilly

News List

EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research biospace
March 09, 2018
The European Foundation for the Study of Diabetes (EFSD), JDRF and Eli Lilly and Company (NYSE: LLY) have agreed to extend their collaboration for the European Programme in Type 1 Diabetes Research through 2020
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the biospace
March 09, 2018
The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four biologics for psoriasis alone
Lilly Exploring Strategic Alternatives for Animal Health Biz biospace
February 02, 2018
Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2017.
Lilly and KeyBioscience collaborate to develop potential type 2 diabetes treatment pharmaceutical-technology
June 13, 2017
US-based Eli Lilly and Company has collaborated with Nordic Bioscience subsidiary KeyBioscience to develop Dual Amylin Calcitonin Receptor Agonists (DACRAs), a potential new class of treatments for patients with metabolic disorders such as type 2 diabetes